Clinical trials: MS
Multiple Sclerosis
Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses
This is a proof of concept, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of Isoxsuprine in MS subjects experiencing a typical relapse.
- Trial name
- NCT03752307
- Testing
- Isoxsuprine Hydrochloride, Corticosteroid
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of New Mexico
Primary Progressive Multiple Sclerosis
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Background: Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system that progressively weakens and destroys the pathways of the nervous system.
- Trial name
- IPPoMS (NCT00950248)
- Testing
- Idebenone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis
Safety of Bryostatin in Patients With MS
This is a single-site, single-arm, single-dose, Phase 1 study of the safety of bryostatin in participants with multiple sclerosis (MS) receiving any disease modifying therapy (DMT).
- Trial name
- NCT06190912
- Testing
- Bryostatin 1
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Robert Fox
Multiple Sclerosis
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
Patients who have been diagnosed with clinically isolated syndrome (CIS) often develop problems related to the central nervous system, which controls the nerves in the body.
- Trial name
- STAYCIS (NCT00094172)
- Testing
- Atorvastatin
- Where
- 14 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord.
- Trial name
- NCT00288626
- Testing
- Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.
- Trial name
- REFLEX (NCT00404352)
- Testing
- RNF
- Where
- 67 sites in Argentina, Australia and 25 more
- Volunteers
- 517 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY)
The aim of this retrospective study is to review and describe safety, tolerability and efficacy of Rebif® (subcutaneous interferon [IFN]-beta-1a) in children and adolescents, using information already recorded in medical records.
- Trial name
- REPLAY (NCT01207648)
- Testing
- Rebif®
- Where
- 18 sites in United States, Argentina and 6 more
- Volunteers
- 307 people
- Sponsor
- EMD Serono
Constipation, Fecal Incontinence
Treating Anorectal Dysfunction in MS
The investigators seek to test whether incorporating the scheduled dosing of a bisacodyl 10 mg rectal suppository every other day improves bowel-related symptoms in patients with multiple sclerosis.
- Conditions
- Constipation, Fecal Incontinence, Multiple Sclerosis
- Trial name
- NCT02609607
- Testing
- Bisacodyl
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- David Levinthal
Relapsing Remitting Multiple Sclerosis
Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis
This was a multicenter, randomized, open-label, parallel-group, active-controlled study. Prior to randomization, participants were to have been treated with glatiramer acetate or interferon β-1a (44 μg).
- Trial name
- SURPASS (NCT01058005)
- Testing
- BG00002 (natalizumab), interferon beta-1a, glatiramer acetate
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 84 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Melatonin in Patients With Multiple Sclerosis (MS).
To date, there are no published data on the role of melatonin supplementation or the appropriate dose for patients with multiple sclerosis.
- Trial name
- NCT03498131
- Testing
- 3 mg Melatonin, 5 mg Melatonin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT03737851
- Testing
- elezanumab
- Where
- 49 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- AbbVie
Multiple Sclerosis
Tele-Exercise and Multiple Sclerosis
The purpose of this study is to compare the effects of two delivery models of an evidence-based complementary alternative medicine (CAM) program that combines neurorehabilitative (functional) exercise, yoga, and Pilates for…
- Trial name
- TEAMS (NCT03117881)
- Testing
- DirectCAM, TeleCAM, rDirectCAM
- Where
- 40 sites in United States
- Volunteers
- 911 people
- Sponsor
- University of Alabama at Birmingham
Multiple Sclerosis (MS)
Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
The objective of this study was to collect data both retrospectively and prospectively in order to evaluate the long-term outcomes, durability of effect, and real-world treatment patterns following treatment with Cladribine…
- Trial name
- NCT03961204
- Testing
- Data Collection
- Where
- 99 sites in United States, Australia and 27 more
- Volunteers
- 662 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Relapsing Multiple Sclerosis
Rebif New Formulation (RNF) Quality of Life (QOL) Study
To evaluate the impact on Quality of Life (QOL), tolerability, treatment satisfaction, and injection site redness Rebif treated subjects with relapsing forms of MS who transition to a new formulation of Rebif (RNF).
- Trial name
- RebiQoL (NCT00472797)
- Testing
- Rebif New Formulation Non Titrated, Rebif New Formulation Titrated
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- EMD Serono
Bladder Dysfunction, Multiple Sclerosis
Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction
The aims of this prospective, randomized study are: To assess the effect of clean intermittent catheterization (CIC) To investigate if MS patients will have symptom reduction (urgency, frequency, nocturia and incontinence) when…
- Trial name
- NCT00913510
- Testing
- CIC using LoFric Primo, Anticholinergic medication
- Where
- 5 sites in Belgium, Germany and 2 more
- Volunteers
- 24 people
- Sponsor
- Wellspect HealthCare
Anticoagulant Therapy
In Vitro Diagnostic Test for DOAC in Urine
This trial is conducted to assess the performance and handling of the in vitro diagnostic (IVD) device for oral direct factor Xa and thrombin inhibitors from urine samples of patients on treatment with direct oral anticoagulants…
- Trial name
- PADOASU (NCT03182829)
- Testing
- DOAC Dipstick
- Where
- 18 sites in Germany
- Volunteers
- 880 people
- Sponsor
- Doasense GmbH
Surgical Acute Wounds
Comparison of Efficacy on Healing, and Safety of Two Dressings Urgotul and TulleGras MS on Surgical Acute Wounds.
Evaluation of non-inferiority on healing rates of two dressings Urgotul and TulleGras MS in the treatment of surgical acute wounds.
- Trial name
- NCT02322710
- Testing
- Urgotul: Low-adherent dressing, TulleGras M.S.: Vaseline gauze
- Where
- 33 sites in France
- Volunteers
- 208 people
- Sponsor
- Mylan Inc.
Multiple Sclerosis
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
MAIN STUDY: The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for…
- Trial name
- NCT01970410
- Testing
- teriflunomide
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis
Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis
The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography…
- Trial name
- NCT01796860
- Testing
- AFO
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Texas Southwestern Medical Center